Literature DB >> 7998769

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

P J Dyck1, W J Litchy, K M Kratz, G A Suarez, P A Low, A A Pineda, A J Windebank, J L Karnes, P C O'Brien.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy is a paralytic syndrome, causing considerable disability and even death. In controlled clinical trials, plasma exchange prevented or ameliorated neurological deficits, but the efficacy of immune globulin infusion remains unproved. Also unknown is whether immune globulin infusion is as effective, or more effective, than plasma exchange and what dosages and frequencies are best. In this observer-blinded study, using some objective end points not subject to bias (e.g., summated compound muscle action potential), 20 patients with progressive or static polyneuropathy were randomly assigned to receive either of the two treatments for 6 weeks, followed by a washout period, and then were assigned to receive the other treatment. Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks) and immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks) were used. End points assessed before and after treatment schedules were neurological disability score; muscle weakness of the neurological disability score; summated compound muscle action potentials of ulnar, median, and peroneal nerves; summated sensory nerve action potentials of ulnar and sural nerves; and vibratory detection threshold of the great toe using CASE IV. Observers were masked as to treatment used. Of 20 patients, 13 received both treatments whereas 4 did not worsen sufficiently to receive the second treatment--1 patient left the study during and 2 after the first treatment to receive unscheduled treatment elsewhere.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998769     DOI: 10.1002/ana.410360607

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  66 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

Review 2.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

3.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 4.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

6.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 7.  Intravenous immunoglobulin in therapy of peripheral neuropathy.

Authors:  Alexander Gorshtein; Yair Levy
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 8.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

9.  Dynametric assessment in CIDP.

Authors:  Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-04       Impact factor: 3.217

Review 10.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.